# Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test

> **NCT05603299** · NA · WITHDRAWN · sponsor: **Qure Healthcare, LLC**

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **OTHER:** Educational Materials on the Dawn test

## Key facts

- **NCT ID:** NCT05603299
- **Lead sponsor:** Qure Healthcare, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-21
- **Primary completion:** 2023-12-18
- **Final completion:** 2023-12-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study recruited no participants due to a pre-recruitment decision by the sponsor to not proceed. Factors considered included logistics, resources, and new research data.
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603299, "Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05603299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*